Olmetec masks underlying weakness at Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Growth for the angiotensin II antagonist Benicar/Olmetec (olmesartan) has again more than made up for weakness elsewhere in Daiichi Sankyo's portfolio. In the six months to September 30th, global sales of the antihypertensive rose by 8% to ¥104.6 billion ($1.06 billion).